Overview of gaps in UK epilepsy research portfolio identified by clinical study groups (CSGs)

**Diagnosis & Aetiology**
- Identification of novel aetiologies (infectious, toxic, autoimmune, etc)
- Development of novel epilepsy models
- Brain maturation and epilepsy
- Novel mechanisms (eg. glia, inflammation)
- Predictive biomarkers of natural history and treatment outcome
- Mechanisms of epilepsy associated with other diseases (eg. vascular, metabolic etc)
- Mechanisms of comorbidities
- Novel diagnostic methods for epilepsy
- Novel diagnostic methods for psychogenic non-epileptic attacks
- Brain development in childhood epilepsy
- Diagnosis and aetiology of comorbid conditions (eg. psychiatric, behavioural)
- Establishment of patient cohorts

**Interventions & Therapies**
- Optimisation of existing treatments
- Novel treatment strategies
- Service delivery
- Improving adherence to treatment
- Psychological interventions
- Assessment of treatment efficacy in people with epilepsy and learning disability
- Treatment and management of psychological co-morbidities
- Development of interventions that prevent, interrupt or reverse the epileptogenic process

**Impact & Outcomes**
- Identification and causes of cognitive impairment
- Identification and causes of co-morbidity
- Development of care models and interventions
- Provision of treatment for cognitive impairment and co-morbidities
- Identification of treatment side effects in people with epilepsy and learning disability
- Determination of impact of psychoeducational programmes
- Development of intervention programmes for psychogenic non-epileptic attack disorder